drugset / Trial / NCT00076856

Temozolomide for Treatment of Brain Metastases From Non-Small Cell Lung Cancer (Study P03247)

NCT00076856 ↗

Phase 2 Completed 95 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to demonstrate improvement in overall survival for the combination of whole brain radiation therapy (WBRT) plus temozolomide (TMZ) versus WBRT alone. Secondary objective is to demonstrate an improvement in the time to radiological CNS progression with the addition of TMZ to WBRT.

Timeline

Start
2004-03-31
Primary completion
2006-03-31
Completion
2006-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Temozolomide Small molecule 75 mg/m2 —